Five-year overall survival and progression-free survival of patients with advanced NSCLC receiving pembrolizumab
Summary. This review will present the latest updated results of the KEYNOTE-024 phase III clinical trial examining the efficacy and safety profile of pembrolizumab compared with chemotherapy as a first-line treatment for patients with advanced non-small cell lung cancer (NSCLC). There are data on the 5-year overall survival of patients receiving pembrolizumab, which were presented at the Virtual Congress of the European Society of Medical Oncology (ESMO) on September 21, 2020, as well as the results of subanalysis of the Japanese patient population for survival without progression published on September 14, 2020 in the journal Cancer Science.
Leave a comment